{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T15:02:30Z","timestamp":1792422150347,"version":"4.5.0"},"reference-count":119,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,6,20]],"date-time":"2023-06-20T00:00:00Z","timestamp":1687219200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["kidney-international.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Kidney International"],"published-print":{"date-parts":[[2023,10]]},"DOI":"10.1016\/j.kint.2023.05.009","type":"journal-article","created":{"date-parts":[[2023,5,24]],"date-time":"2023-05-24T20:57:38Z","timestamp":1684961858000},"page":"655-680","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":139,"title":["Novel anemia therapies in chronic kidney disease: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference"],"prefix":"10.1016","volume":"104","author":[{"given":"Elaine","family":"Ku","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucia","family":"Del Vecchio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kai-Uwe","family":"Eckardt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Volker H.","family":"Haase","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kirsten L.","family":"Johansen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masaomi","family":"Nangaku","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Navdeep","family":"Tangri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sushrut S.","family":"Waikar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrzej","family":"Wi\u0119cek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Cheung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michel","family":"Jadoul","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wolfgang C.","family":"Winkelmayer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David C.","family":"Wheeler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Baris","family":"Afsar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tadao","family":"Akizawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan D.","family":"Anker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mustafa","family":"Arici","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jodie L.","family":"Babitt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan","family":"Barratt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey S.","family":"Berns","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anatole","family":"Besarab","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sunil","family":"Bhandari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher","family":"Brown","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aleix","family":"Cases","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Glenn M.","family":"Chertow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cynthia","family":"Delgado","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tillman B.","family":"Dr\u00fceke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven","family":"Fishbane","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rafael","family":"G\u00f3mez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Morgan E.","family":"Grams","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takayuki","family":"Hamano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chuan-Ming","family":"Hao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raymond K.","family":"Hsu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kunitoshi","family":"Iseki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabelle","family":"Jordans","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edgar V.","family":"Lerma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Locatelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iain C.","family":"Macdougall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jolanta","family":"Ma\u0142yszko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick","family":"Maxwell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lawrence P.","family":"McMahon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregorio T.","family":"Obrador","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marlies","family":"Ostermann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberto","family":"Pecoits-Filho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Farzana","family":"Perwad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon D.","family":"Roger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ajay K.","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Sol\u00e1","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruce S.","family":"Spinowitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mai","family":"Sugahara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshiyuki","family":"Takahashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mototsugu","family":"Tanaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tetsuhiro","family":"Tanaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Der-Cherng","family":"Tarng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcello","family":"Tonelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yusuke","family":"Tsukamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carl P.","family":"Walther","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angela","family":"Yee-Moon Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong","family":"Kong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bradley A.","family":"Warady","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angela C.","family":"Webster","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew R.","family":"Weir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jay B.","family":"Wish","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muh Geot","family":"Wong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.kint.2023.05.009_bib1","doi-asserted-by":"crossref","first-page":"1631","DOI":"10.1681\/ASN.2011111078","article-title":"Mechanisms of anemia in CKD","volume":"23","author":"Babitt","year":"2012","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1016\/j.kint.2023.05.009_bib2","first-page":"279","article-title":"KDIGO Clinical Practice Guideline for Anemia in Chronic Kidney Disease","volume":"2","year":"2012","journal-title":"Kidney Int Suppl"},{"key":"10.1016\/j.kint.2023.05.009_bib3","doi-asserted-by":"crossref","first-page":"1280","DOI":"10.1016\/j.kint.2021.03.020","article-title":"Controversies in optimal anemia management: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Conference","volume":"99","author":"Babitt","year":"2021","journal-title":"Kidney Int"},{"key":"10.1016\/j.kint.2023.05.009_bib4","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1038\/s41581-019-0182-z","article-title":"Mechanisms of hypoxia signalling: new implications for nephrology","volume":"15","author":"Schodel","year":"2019","journal-title":"Nat Rev Nephrol"},{"key":"10.1016\/j.kint.2023.05.009_bib5","doi-asserted-by":"crossref","first-page":"4078","DOI":"10.1111\/bph.13188","article-title":"Prolyl hydroxylase inhibition corrects functional iron deficiency and inflammation-induced anaemia in rats","volume":"172","author":"Barrett","year":"2015","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.kint.2023.05.009_bib6","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.1172\/JCI30117","article-title":"Hypoxia-inducible factor-2 (HIF-2) regulates hepatic erythropoietin in\u00a0vivo","volume":"117","author":"Rankin","year":"2007","journal-title":"J\u00a0Clin Invest"},{"key":"10.1016\/j.kint.2023.05.009_bib7","doi-asserted-by":"crossref","first-page":"1733","DOI":"10.1093\/ndt\/gfs584","article-title":"A\u00a0hepcidin lowering agent mobilizes iron for incorporation into red blood cells in an adenine-induced kidney disease model of anemia in rats","volume":"28","author":"Sun","year":"2013","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.kint.2023.05.009_bib8","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1111\/j.1749-6632.2009.05030.x","article-title":"Pathophysiological consequences of HIF activation: HIF as a modulator of fibrosis","volume":"1177","author":"Haase","year":"2009","journal-title":"Ann NY Acad Sci"},{"key":"10.1016\/j.kint.2023.05.009_bib9","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.kisu.2020.12.002","article-title":"Hypoxia-inducible factor-prolyl hydroxylase inhibitors in the treatment of anemia of chronic kidney disease","volume":"11","author":"Haase","year":"2021","journal-title":"Kidney Int Suppl (2011)"},{"key":"10.1016\/j.kint.2023.05.009_bib10","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.kint.2021.03.019","article-title":"Amelioration of chronic kidney disease-associated anemia by vadadustat in mice is not dependent on erythroferrone","volume":"100","author":"Hanudel","year":"2021","journal-title":"Kidney Int"},{"key":"10.1016\/j.kint.2023.05.009_bib11","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1172\/JCI0215686","article-title":"The gene encoding the iron regulatory peptide hepcidin is regulated by anemia, hypoxia, and inflammation","volume":"110","author":"Nicolas","year":"2002","journal-title":"J\u00a0Clin Invest"},{"key":"10.1016\/j.kint.2023.05.009_bib12","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.1126\/science.1066373","article-title":"A\u00a0conserved family of prolyl-4-hydroxylases that modify HIF","volume":"294","author":"Bruick","year":"2001","journal-title":"Science"},{"key":"10.1016\/j.kint.2023.05.009_bib13","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1053\/j.ajkd.2016.12.011","article-title":"Hypoxia-inducible factor prolyl hydroxylase inhibitors: a potential new treatment for anemia in patients with CKD","volume":"69","author":"Gupta","year":"2017","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.kint.2023.05.009_bib14","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1097\/MNH.0000000000000617","article-title":"Hypoxia-inducible factor prolyl hydroxylase inhibitor in the treatment of anemia in chronic kidney disease","volume":"29","author":"Kurata","year":"2020","journal-title":"Curr Opin Nephrol Hypertens"},{"key":"10.1016\/j.kint.2023.05.009_bib15","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1016\/j.kint.2017.02.035","article-title":"Prolyl hydroxylase domain inhibitors as a novel therapeutic approach against anemia in chronic kidney disease","volume":"92","author":"Sugahara","year":"2017","journal-title":"Kidney Int"},{"key":"10.1016\/j.kint.2023.05.009_bib16","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1053\/j.ajkd.2015.12.020","article-title":"Roxadustat (FG-4592) versus epoetin alfa for anemia in patients receiving maintenance hemodialysis: a phase 2, randomized, 6- to 19-week, open-label, active-comparator, dose-ranging, safety and exploratory efficacy study","volume":"67","author":"Provenzano","year":"2016","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.kint.2023.05.009_bib17","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1681\/ASN.2006090998","article-title":"Inhibition of hypoxia inducible factor hydroxylases protects against renal ischemia-reperfusion injury","volume":"19","author":"Hill","year":"2008","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1016\/j.kint.2023.05.009_bib18","doi-asserted-by":"crossref","first-page":"F1172","DOI":"10.1152\/ajprenal.00667.2011","article-title":"Preischemic targeting of HIF prolyl hydroxylation inhibits fibrosis associated with acute kidney injury","volume":"302","author":"Kapitsinou","year":"2012","journal-title":"Am J Physiol Renal Physiol"},{"key":"10.1016\/j.kint.2023.05.009_bib19","first-page":"CD013751","article-title":"Hypoxia-inducible factor stabilisers for the anaemia of chronic kidney disease","volume":"8","author":"Natale","year":"2022","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.kint.2023.05.009_bib20","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1159\/000513103","article-title":"Daprodustat compared with epoetin beta pegol for anemia in Japanese patients not on dialysis: a 52-week randomized open-label phase 3 trial","volume":"52","author":"Nangaku","year":"2021","journal-title":"Am J Nephrol"},{"key":"10.1016\/j.kint.2023.05.009_bib21","doi-asserted-by":"crossref","first-page":"2313","DOI":"10.1056\/NEJMoa2113380","article-title":"Daprodustat for the treatment of anemia in patients not undergoing dialysis","volume":"385","author":"Singh","year":"2021","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.kint.2023.05.009_bib22","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1159\/000523961","article-title":"Desidustat in anemia due to non-dialysis-dependent chronic kidney disease: a phase 3 study (DREAM-ND)","volume":"53","author":"Agrawal","year":"2022","journal-title":"Am J Nephrol"},{"key":"10.1016\/j.kint.2023.05.009_bib23","doi-asserted-by":"crossref","first-page":"1840","DOI":"10.1016\/j.ekir.2021.04.037","article-title":"A\u00a0phase 3 study of enarodustat in anemic patients with CKD not requiring dialysis: the SYMPHONY ND study","volume":"6","author":"Akizawa","year":"2021","journal-title":"Kidney Int Rep"},{"key":"10.1016\/j.kint.2023.05.009_bib24","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1159\/000518071","article-title":"Efficacy and safety of molidustat for anemia in ESA-naive nondialysis patients: a randomized, phase 3 trial","volume":"52","author":"Yamamoto","year":"2021","journal-title":"Am J Nephrol"},{"key":"10.1016\/j.kint.2023.05.009_bib25","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1159\/000518072","article-title":"Molidustat for renal anemia in nondialysis patients previously treated with erythropoiesis-stimulating agents: a randomized, open-label, phase 3 study","volume":"52","author":"Yamamoto","year":"2021","journal-title":"Am J Nephrol"},{"key":"10.1016\/j.kint.2023.05.009_bib26","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1056\/NEJMoa1813599","article-title":"Roxadustat for anemia in patients with kidney disease not receiving dialysis","volume":"381","author":"Chen","year":"2019","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.kint.2023.05.009_bib27","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1159\/000508100","article-title":"A\u00a0phase 3, multicenter, randomized, two-arm, open-label study of intermittent oral dosing of roxadustat for the treatment of anemia in Japanese erythropoiesis-stimulating agent-naive chronic kidney disease patients not on dialysis","volume":"144","author":"Akizawa","year":"2020","journal-title":"Nephron"},{"key":"10.1016\/j.kint.2023.05.009_bib28","doi-asserted-by":"crossref","first-page":"1810","DOI":"10.1016\/j.ekir.2021.04.003","article-title":"Phase 3 study of roxadustat to treat anemia in non-dialysis-dependent CKD","volume":"6","author":"Akizawa","year":"2021","journal-title":"Kidney Int Rep"},{"key":"10.1016\/j.kint.2023.05.009_bib29","doi-asserted-by":"crossref","first-page":"1629","DOI":"10.1093\/ndt\/gfab057","article-title":"Roxadustat for the treatment of anemia in chronic kidney disease patients not on dialysis: a phase 3, randomized, double-blind, placebo-controlled study (ALPS)","volume":"36","author":"Shutov","year":"2021","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.kint.2023.05.009_bib30","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1016\/j.ekir.2020.11.034","article-title":"Roxadustat for CKD-related anemia in non-dialysis patients","volume":"6","author":"Coyne","year":"2021","journal-title":"Kidney Int Rep"},{"key":"10.1016\/j.kint.2023.05.009_bib31","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1681\/ASN.2020081150","article-title":"Roxadustat for treating anemia in patients with CKD not on dialysis: results from a randomized phase 3 study","volume":"32","author":"Fishbane","year":"2021","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1016\/j.kint.2023.05.009_bib32","doi-asserted-by":"crossref","first-page":"1616","DOI":"10.1093\/ndt\/gfab191","article-title":"Roxadustat for the treatment of anaemia in chronic kidney disease patients not on dialysis: a phase 3, randomized, open-label, active-controlled study (DOLOMITES)","volume":"36","author":"Barratt","year":"2021","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.kint.2023.05.009_bib33","doi-asserted-by":"crossref","first-page":"1779","DOI":"10.1681\/ASN.2020091311","article-title":"Phase 3 randomized study comparing vadadustat with darbepoetin alfa for anemia in Japanese patients with nondialysis-dependent CKD","volume":"32","author":"Nangaku","year":"2021","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1016\/j.kint.2023.05.009_bib34","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1056\/NEJMoa2035938","article-title":"Vadadustat in patients with anemia and non-dialysis-dependent CKD","volume":"384","author":"Chertow","year":"2021","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.kint.2023.05.009_bib35","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.2215\/CJN.16011219","article-title":"Efficacy and safety of daprodustat compared with darbepoetin alfa in Japanese hemodialysis patients with anemia: a randomized, double-blind, phase 3 trial","volume":"15","author":"Akizawa","year":"2020","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.kint.2023.05.009_bib36","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1001\/jamainternmed.2022.0605","article-title":"Efficacy and safety of daprodustat for treatment of anemia of chronic kidney disease in incident dialysis patients: a randomized clinical trial","volume":"182","author":"Singh","year":"2022","journal-title":"JAMA Intern Med"},{"key":"10.1016\/j.kint.2023.05.009_bib37","doi-asserted-by":"crossref","first-page":"2325","DOI":"10.1056\/NEJMoa2113379","article-title":"Daprodustat for the treatment of anemia in patients undergoing dialysis","volume":"385","author":"Singh","year":"2021","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.kint.2023.05.009_bib38","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.2215\/CJN.00550122","article-title":"Three times weekly dosing of daprodustat versus conventional epoetin for treatment of anemia in hemodialysis patients: ASCEND-TD: a phase 3 randomized, double-blind, noninferiority trial","volume":"17","author":"Coyne","year":"2022","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.kint.2023.05.009_bib39","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1159\/000523949","article-title":"Desidustat in anemia due to dialysis-dependent chronic kidney disease: a phase 3 study (DREAM-D)","volume":"53","author":"Gang","year":"2022","journal-title":"Am J Nephrol"},{"key":"10.1016\/j.kint.2023.05.009_bib40","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1159\/000517053","article-title":"A\u00a0phase 3 study of enarodustat (JTZ-951) in Japanese hemodialysis patients for treatment of anemia in chronic kidney disease: SYMPHONY HD study","volume":"7","author":"Akizawa","year":"2021","journal-title":"Kidney Dis (Basel)"},{"key":"10.1016\/j.kint.2023.05.009_bib41","doi-asserted-by":"crossref","first-page":"2604","DOI":"10.1016\/j.ekir.2021.07.015","article-title":"Molidustat for Japanese patients with renal anemia receiving dialysis","volume":"6","author":"Akizawa","year":"2021","journal-title":"Kidney Int Rep"},{"key":"10.1016\/j.kint.2023.05.009_bib42","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1056\/NEJMoa1901713","article-title":"Roxadustat treatment for anemia in patients undergoing long-term dialysis","volume":"381","author":"Chen","year":"2019","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.kint.2023.05.009_bib43","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1111\/1744-9987.13468","article-title":"Oral roxadustat three times weekly in ESA-naive and ESA-converted patients with anemia of chronic kidney disease on hemodialysis: results from two phase 3 studies","volume":"24","author":"Akizawa","year":"2020","journal-title":"Ther Apher Dial"},{"key":"10.1016\/j.kint.2023.05.009_bib44","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1111\/1744-9987.12888","article-title":"Intermittent oral dosing of roxadustat in peritoneal dialysis chronic kidney disease patients with anemia: a randomized, phase 3, multicenter, open-label study","volume":"24","author":"Akizawa","year":"2020","journal-title":"Ther Apher Dial"},{"key":"10.1016\/j.kint.2023.05.009_bib45","doi-asserted-by":"crossref","first-page":"1628","DOI":"10.1681\/ASN.2019060623","article-title":"Phase 3, randomized, double-blind, active-comparator (darbepoetin alfa) study of oral roxadustat in CKD patients with anemia on hemodialysis in Japan","volume":"31","author":"Akizawa","year":"2020","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1016\/j.kint.2023.05.009_bib46","doi-asserted-by":"crossref","first-page":"1717","DOI":"10.1093\/ndt\/gfab051","article-title":"Roxadustat for anemia in patients with end-stage renal disease incident to dialysis","volume":"36","author":"Provenzano","year":"2021","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.kint.2023.05.009_bib47","doi-asserted-by":"crossref","first-page":"5361","DOI":"10.1007\/s12325-021-01904-6","article-title":"Roxadustat for the maintenance treatment of anemia in patients with end-stage kidney disease on stable dialysis: a European phase 3, randomized, open-label, active-controlled study (PYRENEES)","volume":"38","author":"Csiky","year":"2021","journal-title":"Adv Ther"},{"key":"10.1016\/j.kint.2023.05.009_bib48","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1681\/ASN.2020111638","article-title":"Roxadustat versus epoetin alfa for treating anemia in patients with chronic kidney disease on dialysis: results from the randomized phase 3 ROCKIES study","volume":"33","author":"Fishbane","year":"2022","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1016\/j.kint.2023.05.009_bib49","doi-asserted-by":"crossref","first-page":"1829","DOI":"10.1016\/j.ekir.2021.04.007","article-title":"A\u00a0randomized trial of roxadustat in anemia of kidney failure: SIERRAS study","volume":"6","author":"Charytan","year":"2021","journal-title":"Kidney Int Rep"},{"key":"10.1016\/j.kint.2023.05.009_bib50","doi-asserted-by":"crossref","first-page":"1731","DOI":"10.1093\/ndt\/gfab055","article-title":"Efficacy and safety of vadadustat compared with darbepoetin alfa in Japanese anemic patients on hemodialysis: a phase 3, multicenter, randomized, double-blind study","volume":"36","author":"Nangaku","year":"2021","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.kint.2023.05.009_bib51","doi-asserted-by":"crossref","first-page":"1601","DOI":"10.1056\/NEJMoa2025956","article-title":"Safety and efficacy of vadadustat for anemia in patients undergoing dialysis","volume":"384","author":"Eckardt","year":"2021","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.kint.2023.05.009_bib52","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1056\/NEJMra1510063","article-title":"Challenges in the design and interpretation of noninferiority trials","volume":"377","author":"Mauri","year":"2017","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.kint.2023.05.009_bib53","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1159\/000496929","article-title":"A\u00a0placebo-controlled, randomized trial of enarodustat in patients with chronic kidney disease followed by long-term trial","volume":"49","author":"Akizawa","year":"2019","journal-title":"Am J Nephrol"},{"key":"10.1016\/j.kint.2023.05.009_bib54","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1111\/1744-9987.13627","article-title":"Molidustat for anemia correction in Japanese patients undergoing hemodialysis: a single-arm, phase 3 study","volume":"25","author":"Akizawa","year":"2021","journal-title":"Ther Apher Dial"},{"key":"10.1016\/j.kint.2023.05.009_bib55","doi-asserted-by":"crossref","first-page":"28","DOI":"10.2215\/CJN.02510218","article-title":"Effects of molidustat in the treatment of anemia in CKD","volume":"14","author":"Macdougall","year":"2019","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.kint.2023.05.009_bib56","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1111\/1744-9987.13686","article-title":"Efficacy and safety of daprodustat in Japanese peritoneal dialysis patients","volume":"25","author":"Kanai","year":"2021","journal-title":"Ther Apher Dial"},{"key":"10.1016\/j.kint.2023.05.009_bib57","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1056\/NEJM199808273390903","article-title":"The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin","volume":"339","author":"Besarab","year":"1998","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.kint.2023.05.009_bib58","doi-asserted-by":"crossref","first-page":"2071","DOI":"10.1056\/NEJMoa062276","article-title":"Normalization of hemoglobin level in patients with chronic kidney disease and anemia","volume":"355","author":"Dr\u00fceke","year":"2006","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.kint.2023.05.009_bib59","doi-asserted-by":"crossref","first-page":"2085","DOI":"10.1056\/NEJMoa065485","article-title":"Correction of anemia with epoetin alfa in chronic kidney disease","volume":"355","author":"Singh","year":"2006","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.kint.2023.05.009_bib60","doi-asserted-by":"crossref","first-page":"2019","DOI":"10.1056\/NEJMoa0907845","article-title":"A\u00a0trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease","volume":"361","author":"Pfeffer","year":"2009","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.kint.2023.05.009_bib61","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1056\/NEJMoa1810742","article-title":"Intravenous iron in patients undergoing maintenance hemodialysis","volume":"380","author":"Macdougall","year":"2019","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.kint.2023.05.009_bib62","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.kisu.2020.12.003","article-title":"Iron metabolism and management: focus on chronic kidney disease","volume":"11","author":"Agarwal","year":"2021","journal-title":"Kidney Int Suppl (2011)"},{"key":"10.1016\/j.kint.2023.05.009_bib63","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1159\/000454818","article-title":"Effects of daprodustat, a novel hypoxia-inducible factor prolyl hydroxylase inhibitor on anemia management in Japanese hemodialysis subjects","volume":"45","author":"Akizawa","year":"2017","journal-title":"Am J Nephrol"},{"key":"10.1016\/j.kint.2023.05.009_bib64","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1681\/ASN.2015030241","article-title":"Roxadustat (FG-4592): correction of anemia in incident dialysis patients","volume":"27","author":"Besarab","year":"2016","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1016\/j.kint.2023.05.009_bib65","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.1681\/ASN.2014111139","article-title":"Four-week studies of oral hypoxia-inducible factor-prolyl hydroxylase inhibitor GSK1278863 for treatment of anemia","volume":"27","author":"Holdstock","year":"2016","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1016\/j.kint.2023.05.009_bib66","doi-asserted-by":"crossref","first-page":"1694","DOI":"10.1093\/ndt\/gfab050","article-title":"Serum biomarkers of iron stores are associated with worse physical health-related quality of life in nondialysis-dependent chronic kidney disease patients with or without anemia","volume":"36","author":"Guedes","year":"2021","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.kint.2023.05.009_bib67","doi-asserted-by":"crossref","first-page":"2020","DOI":"10.1681\/ASN.2020101531","article-title":"Serum biomarkers of iron stores are associated with increased risk of all-cause mortality and cardiovascular events in nondialysis CKD patients, with or without anemia","volume":"32","author":"Guedes","year":"2021","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1016\/j.kint.2023.05.009_bib68","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1016\/j.kint.2023.02.019","article-title":"The ASCEND-NHQ trial found positive effects of daprodustat on hemoglobin and quality of life in patients with non-dialysis-dependent chronic kidney disease","volume":"103","author":"Johansen","year":"2023","journal-title":"Kidney Int"},{"key":"10.1016\/j.kint.2023.05.009_bib71","doi-asserted-by":"crossref","first-page":"1190","DOI":"10.2215\/CJN.16191020","article-title":"Efficacy and cardiovascular safety of roxadustat for treatment of anemia in patients with non-dialysis-dependent CKD: pooled results of three randomized clinical trials","volume":"16","author":"Provenzano","year":"2021","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.kint.2023.05.009_bib72","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.2215\/CJN.08280621","article-title":"Cardiovascular safety of roxadustat in CKD anemia: a fig leaf named noninferiority","volume":"16","author":"Winkelmayer","year":"2021","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.kint.2023.05.009_bib73","first-page":"2482","article-title":"Daprodustat and on-treatment cardiovascular events in chronic kidney disease. Reply","volume":"387","author":"McCausland","year":"2022","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.kint.2023.05.009_bib74","doi-asserted-by":"crossref","first-page":"5345","DOI":"10.1007\/s12325-021-01903-7","article-title":"Efficacy and cardiovascular safety of roxadustat in dialysis-dependent chronic kidney disease: pooled analysis of four phase 3 studies","volume":"38","author":"Barratt","year":"2021","journal-title":"Adv Ther"},{"key":"10.1016\/j.kint.2023.05.009_bib122","doi-asserted-by":"crossref","first-page":"1546","DOI":"10.1007\/s12325-023-02433-0","article-title":"Safety of roxadustat versus erythropoiesis-stimulating agents in patients with anemia of non-dialysis-dependent or incident-to-dialysis chronic kidney disease: pooled analysis of four phase 3 studies","volume":"40","author":"Barratt","year":"2023","journal-title":"Adv Ther"},{"key":"10.1016\/j.kint.2023.05.009_bib75","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1016\/j.ekir.2020.12.018","article-title":"Retraction notice to \"Pooled Analysis of Roxadustat for Anemia in Patients With Kidney Failure Incident to Dialysis.\"","volume":"6","author":"Provenzano","year":"2021","journal-title":"Kidney Int Rep"},{"key":"10.1016\/j.kint.2023.05.009_bib77","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1111\/nep.13835","article-title":"Recommendations by the Asian Pacific Society of Nephrology (APSN) on the appropriate use of HIF-PH inhibitors","volume":"26","author":"Yap","year":"2021","journal-title":"Nephrology (Carlton)"},{"key":"10.1016\/j.kint.2023.05.009_bib78","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1161\/CIRCRESAHA.119.316453","article-title":"Iron-deficiency and estrogen are associated with ischemic stroke by up-regulating transferrin to induce hypercoagulability","volume":"127","author":"Tang","year":"2020","journal-title":"Circ Res"},{"key":"10.1016\/j.kint.2023.05.009_bib79","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.thromres.2019.07.013","article-title":"The stimulation of thrombosis by hypoxia","volume":"181","author":"Gupta","year":"2019","journal-title":"Thromb Res"},{"key":"10.1016\/j.kint.2023.05.009_bib81","doi-asserted-by":"crossref","DOI":"10.1111\/apha.13668","article-title":"Pharmacological HIF-PHD inhibition reduces renovascular resistance and increases glomerular filtration by stimulating nitric oxide generation","volume":"233","author":"Burmakin","year":"2021","journal-title":"Acta Physiol (Oxf)"},{"key":"10.1016\/j.kint.2023.05.009_bib82","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0111838","article-title":"Mimicking hypoxia to treat anemia: HIF-stabilizer BAY 85-3934 (Molidustat) stimulates erythropoietin production without hypertensive effects","volume":"9","author":"Flamme","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.kint.2023.05.009_bib83","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.133690","article-title":"Roxadustat prevents Ang II hypertension by targeting angiotensin receptors and eNOS","volume":"6","author":"Yu","year":"2021","journal-title":"JCI Insight"},{"key":"10.1016\/j.kint.2023.05.009_bib84","doi-asserted-by":"crossref","first-page":"9382","DOI":"10.1074\/jbc.M117.788562","article-title":"Hypoxia-inducible factor 1alpha activates insulin-induced gene 2 (Insig-2) transcription for degradation of 3-hydroxy-3-methylglutaryl (HMG)-CoA reductase in the liver","volume":"292","author":"Hwang","year":"2017","journal-title":"J\u00a0Biol Chem"},{"key":"10.1016\/j.kint.2023.05.009_bib85","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1042\/BJ20111377","article-title":"Hypoxia-inducible factor-1 (HIF-1) promotes LDL and VLDL uptake through inducing VLDLR under hypoxia","volume":"441","author":"Shen","year":"2012","journal-title":"Biochem J"},{"key":"10.1016\/j.kint.2023.05.009_bib86","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1111\/1744-9987.13724","article-title":"Two long-term phase 3 studies of enarodustat (JTZ-951) in Japanese anemic patients with chronic kidney disease not on dialysis or on maintenance hemodialysis: SYMPHONY ND-Long and HD-Long studies","volume":"26","author":"Akizawa","year":"2022","journal-title":"Ther Apher Dial"},{"key":"10.1016\/j.kint.2023.05.009_bib87","article-title":"Vadadustat, an oral hypoxia-inducible factor prolyl hydroxylase inhibitor, for treatment of anemia of chronic kidney disease: two randomized phase 2 trials in Japanese patients","author":"Nangaku","year":"2020","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.kint.2023.05.009_bib88","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1159\/000345932","article-title":"Is lipid management effective for all stages of CKD?","volume":"35","author":"Ku","year":"2013","journal-title":"Blood Purif"},{"key":"10.1016\/j.kint.2023.05.009_bib89","doi-asserted-by":"crossref","DOI":"10.1016\/j.gene.2021.145796","article-title":"Up-down regulation of HIF-1\u03b1 in cancer progression","volume":"798","author":"Rashid","year":"2021","journal-title":"Gene"},{"key":"10.1016\/j.kint.2023.05.009_bib90","doi-asserted-by":"crossref","first-page":"3895","DOI":"10.2174\/138161209789649394","article-title":"The VHL tumor suppressor: master regulator of HIF","volume":"15","author":"Haase","year":"2009","journal-title":"Curr Pharm Des"},{"key":"10.1016\/j.kint.2023.05.009_bib91","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1007\/978-3-319-75402-4_22","article-title":"The role of hypoxia, hypoxia-inducible factor (HIF), and VEGF in retinal angiomatous proliferation","volume":"1074","author":"Barben","year":"2018","journal-title":"Adv Exp Med Biol"},{"key":"10.1016\/j.kint.2023.05.009_bib92","first-page":"5071","article-title":"Effects of HIF-1alpha on diabetic retinopathy angiogenesis and VEGF expression","volume":"22","author":"Zhang","year":"2018","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"10.1016\/j.kint.2023.05.009_bib93","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1016\/j.ekir.2022.01.1045","article-title":"Two phase 3 studies on ophthalmologic effects of roxadustat versus darbepoetin","volume":"7","author":"Sepah","year":"2022","journal-title":"Kidney Int Rep"},{"key":"10.1016\/j.kint.2023.05.009_bib94","doi-asserted-by":"crossref","first-page":"1665","DOI":"10.1093\/ndt\/gfv302","article-title":"Randomized placebo-controlled dose-ranging and pharmacodynamics study of roxadustat (FG-4592) to treat anemia in nondialysis-dependent chronic kidney disease (NDD-CKD) patients","volume":"30","author":"Besarab","year":"2015","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.kint.2023.05.009_bib95","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1093\/ckj\/sfy014","article-title":"Daprodustat for anemia: a 24-week, open-label, randomized controlled trial in participants on hemodialysis","volume":"12","author":"Meadowcroft","year":"2019","journal-title":"Clin Kidney J"},{"key":"10.1016\/j.kint.2023.05.009_bib96","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1016\/j.kint.2016.07.019","article-title":"Vadadustat, a novel oral HIF stabilizer, provides effective anemia treatment in nondialysis-dependent chronic kidney disease","volume":"90","author":"Pergola","year":"2016","journal-title":"Kidney Int"},{"key":"10.1016\/j.kint.2023.05.009_bib97","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1186\/s12882-021-02304-2","article-title":"Suppression of thyrotropin secretion during roxadustat treatment for renal anemia in a patient undergoing hemodialysis","volume":"22","author":"Ichii","year":"2021","journal-title":"BMC Nephrol"},{"key":"10.1016\/j.kint.2023.05.009_bib98","doi-asserted-by":"crossref","first-page":"1472","DOI":"10.1093\/ckj\/sfab007","article-title":"Roxadustat and thyroid-stimulating hormone suppression","volume":"14","author":"Tokuyama","year":"2021","journal-title":"Clin Kidney J"},{"key":"10.1016\/j.kint.2023.05.009_bib99","first-page":"gfad017","article-title":"Suppression of thyroid profile during roxadustat treatment in chronic kidney disease patients","author":"Cheng","year":"2023","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.kint.2023.05.009_bib100","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1111\/1744-9987.13611","article-title":"Vadadustat for anemia in chronic kidney disease patients on peritoneal dialysis: a phase 3 open-label study in Japan","volume":"25","author":"Nangaku","year":"2021","journal-title":"Ther Apher Dial"},{"key":"10.1016\/j.kint.2023.05.009_bib101","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1111\/1744-9987.13699","article-title":"A\u00a0phase 3, open-label, single-arm study of vadadustat for anemia in chronic kidney disease for Japanese patients on hemodialysis not receiving erythropoiesis-stimulating agents","volume":"26","author":"Nangaku","year":"2022","journal-title":"Ther Apher Dial"},{"key":"10.1016\/j.kint.2023.05.009_bib102","doi-asserted-by":"crossref","DOI":"10.1016\/j.crphar.2022.100102","article-title":"Prolyl hydroxylase inhibitor desidustat improves anemia in erythropoietin hyporesponsive state","volume":"3","author":"Joharapurkar","year":"2022","journal-title":"Curr Res Pharmacol Drug Discov"},{"key":"10.1016\/j.kint.2023.05.009_bib103","doi-asserted-by":"crossref","first-page":"1699","DOI":"10.1007\/s00467-010-1538-6","article-title":"Risk for anemia in pediatric chronic kidney disease patients: a report of NAPRTCS","volume":"25","author":"Atkinson","year":"2010","journal-title":"Pediatr Nephrol"},{"key":"10.1016\/j.kint.2023.05.009_bib104","doi-asserted-by":"crossref","first-page":"3520","DOI":"10.1093\/ndt\/gfl479","article-title":"Increased injection pain with darbepoetin-alpha compared to epoetin-beta in paediatric dialysis patients","volume":"21","author":"Schmitt","year":"2006","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.kint.2023.05.009_bib105","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1007\/s00467-017-3849-3","article-title":"HIF stabilizers in the management of renal anemia: from bench to bedside to pediatrics","volume":"34","author":"Kular","year":"2019","journal-title":"Pediatr Nephrol"},{"key":"10.1016\/j.kint.2023.05.009_bib106","doi-asserted-by":"crossref","DOI":"10.1016\/j.cellsig.2020.109524","article-title":"Role of oxygen and the HIF-pathway in polycystic kidney disease","volume":"69","author":"Buchholz","year":"2020","journal-title":"Cell Signal"},{"key":"10.1016\/j.kint.2023.05.009_bib107","doi-asserted-by":"crossref","first-page":"2157","DOI":"10.1093\/ndt\/gfab318","article-title":"The ASCEND-ND trial: study design and participant characteristics","volume":"37","author":"Perkovic","year":"2022","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.kint.2023.05.009_bib108","doi-asserted-by":"crossref","first-page":"3716","DOI":"10.1172\/JCI84433","article-title":"Hypoxia-dependent regulation of inflammatory pathways in immune cells","volume":"126","author":"Taylor","year":"2016","journal-title":"J\u00a0Clin Invest"},{"key":"10.1016\/j.kint.2023.05.009_bib109","doi-asserted-by":"crossref","first-page":"356","DOI":"10.2337\/dc17-1096","article-title":"How does empagliflozin reduce cardiovascular mortality? Insights from a mediation analysis of the EMPA-REG OUTCOME trial","volume":"41","author":"Inzucchi","year":"2018","journal-title":"Diabetes Care"},{"key":"10.1016\/j.kint.2023.05.009_bib110","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1016\/j.kint.2020.04.051","article-title":"Mediators of the effects of canagliflozin on kidney protection in patients with type 2 diabetes","volume":"98","author":"Li","year":"2020","journal-title":"Kidney Int"},{"key":"10.1016\/j.kint.2023.05.009_bib111","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.jchf.2019.08.004","article-title":"Mediators of the effects of canagliflozin on heart failure in patients with type 2 diabetes","volume":"8","author":"Li","year":"2020","journal-title":"JACC Heart Fail"},{"key":"10.1016\/j.kint.2023.05.009_bib112","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1159\/000507272","article-title":"Competing effects of renin angiotensin system blockade and sodium-glucose cotransporter-2 inhibitors on erythropoietin secretion in diabetes","volume":"51","author":"Marathias","year":"2020","journal-title":"Am J Nephrol"},{"key":"10.1016\/j.kint.2023.05.009_bib113","doi-asserted-by":"crossref","DOI":"10.1016\/j.jdiacomp.2020.107729","article-title":"Correction of anemia by dapagliflozin in patients with type 2 diabetes","volume":"34","author":"Stefansson","year":"2020","journal-title":"J\u00a0Diabetes Complications"},{"key":"10.1016\/j.kint.2023.05.009_bib114","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","article-title":"Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes","volume":"373","author":"Zinman","year":"2015","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.kint.2023.05.009_bib115","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1161\/CIRCULATIONAHA.120.047077","article-title":"Dapagliflozin and diuretic use in patients with heart failure and reduced ejection fraction in DAPA-HF","volume":"142","author":"Jackson","year":"2020","journal-title":"Circulation"},{"key":"10.1016\/j.kint.2023.05.009_bib116","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1002\/ejhf.2132","article-title":"Effect of dapagliflozin on anaemia in DAPA-HF","volume":"23","author":"Docherty","year":"2021","journal-title":"Eur J Heart Fail"},{"issue":"6","key":"10.1016\/j.kint.2023.05.009_bib123","doi-asserted-by":"crossref","DOI":"10.1056\/EVIDoa2300049","article-title":"Dapagliflozin and anemia in patients with chronic kidney disease","volume":"2","author":"Koshino","year":"2023","journal-title":"NEJM Evid"},{"key":"10.1016\/j.kint.2023.05.009_bib117","doi-asserted-by":"crossref","first-page":"771","DOI":"10.2337\/dc16-2724","article-title":"Renal handling of ketones in response to sodium-glucose cotransporter 2 inhibition in patients with type 2 diabetes","volume":"40","author":"Ferrannini","year":"2017","journal-title":"Diabetes Care"},{"key":"10.1016\/j.kint.2023.05.009_bib118","doi-asserted-by":"crossref","first-page":"dgaa057","DOI":"10.1210\/clinem\/dgaa057","article-title":"Dapagliflozin suppresses hepcidin and increases erythropoiesis","volume":"105","author":"Ghanim","year":"2020","journal-title":"J\u00a0Clin Endocrinol Metab"},{"key":"10.1016\/j.kint.2023.05.009_bib119","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1111\/dom.12127","article-title":"Dapagliflozin a glucose-regulating drug with diuretic properties in subjects with type 2 diabetes","volume":"15","author":"Lambers Heerspink","year":"2013","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.kint.2023.05.009_bib120","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1089\/dia.2019.0212","article-title":"Canagliflozin improves erythropoiesis in diabetes patients with anemia of chronic kidney disease","volume":"21","author":"Maruyama","year":"2019","journal-title":"Diabetes Technol Ther"},{"key":"10.1016\/j.kint.2023.05.009_bib121","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1016\/S2213-8587(20)30300-4","article-title":"Effects of canagliflozin on anaemia in patients with type 2 diabetes and chronic kidney disease: a post-hoc analysis from the CREDENCE trial","volume":"8","author":"Oshima","year":"2020","journal-title":"Lancet Diabetes Endocrinol"}],"container-title":["Kidney International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0085253823003794?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0085253823003794?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T01:06:16Z","timestamp":1758762376000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0085253823003794"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10]]},"references-count":119,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2023,10]]}},"alternative-id":["S0085253823003794"],"URL":"https:\/\/doi.org\/10.1016\/j.kint.2023.05.009","relation":{},"ISSN":["0085-2538"],"issn-type":[{"value":"0085-2538","type":"print"}],"subject":[],"published":{"date-parts":[[2023,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Novel anemia therapies in chronic kidney disease: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference","name":"articletitle","label":"Article Title"},{"value":"Kidney International","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.kint.2023.05.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Kidney Disease: Improving Global Outcomes (KDIGO). Published by Elsevier Inc. on behalf of the International Society of Nephrology.","name":"copyright","label":"Copyright"}]}}